Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Bayer on the prowl for weaker prey
Bayer appears to be working under Warren Buffett's market-turmoil philosophy: Be fearful when others are greedy and greedy only when others are fearful. The German conglomerate's healthcare unit says it's in an ideal position to capitalize on frightened markets, and it plans to take advantage of the financial stress by snapping up weaker companies.
Bayer Healthcare CEO Arthur Higgins told the Wall Street Journal that his company is mostly interested in businesses that make over-the-counter meds, veterinary drugs and medical devices. That's because Bayer already has a strong prescription drug business, Higgins explained, and would only look at companies that make prescription meds if they carry a significant upside.
"Despite some of the uncertainties that are obviously in the financial markets at the moment, we're in a very strong position to take advantage of the weakness in some other companies," Higgins said. Opportunities should arise in the next "six to 24 months," he said.
- read the WSJ story
Related Articles:
Bayer CEO scoffs at takeover talk
Bayer up on Pfizer buyout talk
Bayer AG grabs Direvo in $298M buyout
Bayer lower 2008 expectations
Bayer plans to beef up biotech pipeline (Jan. 2007)
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


